CN1092937A - A kind of antiviral coating that can be used for the latex viral barrier items such barrier item - Google Patents
A kind of antiviral coating that can be used for the latex viral barrier items such barrier item Download PDFInfo
- Publication number
- CN1092937A CN1092937A CN93103567A CN93103567A CN1092937A CN 1092937 A CN1092937 A CN 1092937A CN 93103567 A CN93103567 A CN 93103567A CN 93103567 A CN93103567 A CN 93103567A CN 1092937 A CN1092937 A CN 1092937A
- Authority
- CN
- China
- Prior art keywords
- latex
- alkyl
- barrier item
- weight
- disinfectant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000004888 barrier function Effects 0.000 title claims description 22
- 239000004816 latex Substances 0.000 title claims description 22
- 229920000126 latex Polymers 0.000 title claims description 22
- 230000003612 virological effect Effects 0.000 title claims description 10
- 230000000840 anti-viral effect Effects 0.000 title abstract description 6
- 239000011248 coating agent Substances 0.000 title description 2
- 238000000576 coating method Methods 0.000 title description 2
- 239000000645 desinfectant Substances 0.000 claims abstract description 19
- 239000000839 emulsion Substances 0.000 claims abstract description 18
- -1 alkylbenzene methyl quaternary ammonium halide Chemical class 0.000 claims abstract description 13
- 239000002562 thickening agent Substances 0.000 claims abstract description 9
- 239000003093 cationic surfactant Substances 0.000 claims abstract description 5
- 239000007822 coupling agent Substances 0.000 claims abstract description 5
- 239000004902 Softening Agent Substances 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims description 38
- 241000700605 Viruses Species 0.000 claims description 28
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 239000004094 surface-active agent Substances 0.000 claims description 9
- 230000002155 anti-virotic effect Effects 0.000 claims description 6
- 235000011187 glycerol Nutrition 0.000 claims description 5
- 230000002159 abnormal effect Effects 0.000 claims description 4
- 239000002736 nonionic surfactant Substances 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 230000036541 health Effects 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 230000000069 prophylactic effect Effects 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims 4
- XIWFQDBQMCDYJT-UHFFFAOYSA-M benzyl-dimethyl-tridecylazanium;chloride Chemical group [Cl-].CCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 XIWFQDBQMCDYJT-UHFFFAOYSA-M 0.000 claims 2
- 229940032912 zephiran Drugs 0.000 claims 2
- 238000005660 chlorination reaction Methods 0.000 claims 1
- 230000001681 protective effect Effects 0.000 claims 1
- 241000124008 Mammalia Species 0.000 abstract description 3
- 239000006210 lotion Substances 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 15
- 210000003491 skin Anatomy 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 210000002845 virion Anatomy 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 241000725303 Human immunodeficiency virus Species 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000002779 inactivation Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 235000004237 Crocus Nutrition 0.000 description 4
- 241000596148 Crocus Species 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- HNLXNOZHXNSSPN-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCOCCOCCOCCOCCOCCO)C=C1 HNLXNOZHXNSSPN-UHFFFAOYSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229920002114 octoxynol-9 Polymers 0.000 description 3
- 229940098514 octoxynol-9 Drugs 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 230000001018 virulence Effects 0.000 description 3
- 241001116389 Aloe Species 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 241000489523 Veratrum Species 0.000 description 2
- ABUBSBSOTTXVPV-UHFFFAOYSA-H [U+6].CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O Chemical compound [U+6].CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O ABUBSBSOTTXVPV-UHFFFAOYSA-H 0.000 description 2
- 235000011399 aloe vera Nutrition 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000036436 anti-hiv Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 230000029052 metamorphosis Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 238000005199 ultracentrifugation Methods 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical group C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 231100000645 Reed–Muench method Toxicity 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000290333 Vanilla fragrans Species 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- 241000726445 Viroids Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- OCBHHZMJRVXXQK-UHFFFAOYSA-M benzyl-dimethyl-tetradecylazanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 OCBHHZMJRVXXQK-UHFFFAOYSA-M 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000036576 dermal application Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- YLGXILFCIXHCMC-JHGZEJCSSA-N methyl cellulose Chemical compound COC1C(OC)C(OC)C(COC)O[C@H]1O[C@H]1C(OC)C(OC)C(OC)OC1COC YLGXILFCIXHCMC-JHGZEJCSSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 229960003730 methylcellulose (4000 cps) Drugs 0.000 description 1
- 229920000847 nonoxynol Polymers 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 229940066429 octoxynol Drugs 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000037075 skin appearance Effects 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 108010050327 trypticase-soy broth Proteins 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
A kind of antiviral emulsion or lotion that is applied to mammal skin, be used for as under the skin protection utensils such as surgical glove or sheath, contain very a spot of a kind of alkylbenzene methyl quaternary ammonium halide disinfectant that skin can tolerate, acceptable nonionic of the skin that a kind of amount is very little or cationic surfactant, a kind of thickener such as ultrasonic coupling agent, a kind of softening agent such as G ﹠ W.
Description
The present invention relates to antiviral composition, relate in particular to the antiviral composition that is exclusively used in mammal skin appearance topical application.
One of main path of propagating between health of virus causes because of the contact of solid table and body fluid mix, as viruses such as liver viroids, herpes virus, HID all whereby approach propagate.Especially the working healthily personnel have the danger that suffers this type of virus disseminating, and as these type of personnel such as rescue personnel, nurse, doctor, operation theater workers, they must participate in and often continuously be engaged in Body contact with the virus infections person.So far, the mode of the most normal recommended anti-this type of virus infections is that protection skin screen is defended the doctrine always, and just the emgloves that is used by the healthcare worker and those are exposed to the latex prophylactic that the viral personnel that spread through sex intercourse use.
Yet still there is to a certain degree worry in people to the usefulness of this class skin protection utensil.If this appliances in use requires to reach the sensitivity of being allowed, just must be as thin as a wafer.This latex utensil is thin more, and the danger that they are subjected to mechanical damage is just big more, and they are also big more to danger that the virion that is comprised has infiltration in various degree.In addition, no matter how carefully make and preserve this class barrier item, still usually exist the risk that too much hole can appear in the utensil situation.
Purpose of the present invention is the effect that will strengthen this type of latex skin barrier item, to prevent the propagation of harmful virus between human body.
The invention provides one and unite the antivirus gel prescription of use with viral barrier item and emgloves and sheath.This prescription and a kind of and be with water base skin can accept carrier mass to be mixed with semi-solid gel, but it contains the strong disinfectant or the antibacterial material of the skin receiving amount of minute quantity, and this prescription is applied on the mammalian skin under viral barrier item such as emgloves and the sheath.This disinfectant or antibacterial material even can accept to kill harmful virus of contact under the required necessary low concentration of composition of the present invention at skin.Thereby the user is provided a kind of duplicate protection, with resist must contact the virus infections of infected individuals, this duplicate protection is viral barrier item and is coated in antibacterial agent or disinfectant gel below it.
Therefore, according to the present invention, from an aspect, a kind of latex barrier item that is applicable to certain position of health that is provided has suppressed virus and has propagated to the there, above-mentioned latex utensil has an outer surface and an inner surface that contacts with body part, above-mentioned inner surface has one deck semisolid, antivirus gel or missible oil, it contains 0.005~0.1%(weight of having an appointment) alkylbenzene methyl quaternary ammonium halide disinfectant, about 0.01~0.1%(weight) nonionic or cationic surfactant, and a kind of lubricated nontoxic abnormal former water-soluble thickener and water, wherein amounts of thickener should make that composition has semisolid, the missible oil denseness.
Being used for alkylbenzene methyl quaternary ammonium halide disinfectant of the present invention is a kind of compound known, in the past a variety of sterilisation purposes of being sold and being used for non-skin contact application in this compounds.Thereby the purpose of selling this compounds is to be used to make wash the local detergent with sterilizing of floor, wall, operating table surface or the like, avoids strong warning that it is contacted with skin as far as possible but often have prompting.In the time of as class brute force skin antiseptic, they also have strong toxicity and skin irritation.By the present invention, when this compounds was present in the prescription with the acceptable low concentration of skin, they can be killed as hepatitis, herpe simplex 1 type and 2 types and HIV virus.In fact, be independent of and be not difficult to be killed when outside body fluid or secretion exist when running into these viruses.May effectively have been killed hardly and after they have infected body of mammals and have begun to duplicate in somatic cell, just become.If be captured and handle in the process that virus can be propagated, just be subjected to killing of general disinfectant easily, as the compound that uses in the present invention between human body.
For avoiding occurring skin irritatin, strong disinfectant is preferably in the present composition and uses, and measures the weight ratio into 0.005-0.5%(); Optimum amount is the 0.005-0.001%(weight ratio).The concrete representation compound of the strong disinfectant of this class of Shi Yonging comprises alkyl-dimethyl benzyl ammonium chloride and alkyl dimethyl ethylbenzylammonium chloride in the present invention, and wherein the moieties chain length is C
12-C
18, comprise its mixture and myristylbenzalkonium chloride.The appropriate mixture of these compounds can have been bought from the market, and its commodity are called MAQUAT MQ2525M-50%, the registration of Si Zhou Chicago, Illinois Mason (Mason) chemical company; Another commodity are called BTC 2125M Illinois Si Zhou, North Field, Stepan register of company.
Also comprised a kind of a spot of nonionic or cationic surfactant in the present composition, it plays a kind of disinfectant lubricant, and it has increased disinfectant sending out in the dermal application zone.Prescription consumption and disinfectant that surfactant suits are approaching, i.e. the 0.01-0.1%(weight ratio), be preferably the 0.01-0.05%(weight ratio).The useful concrete representative of surfactant of this class comprise the polyoxyethylene fundamental mode as octoxynol series, belong to Polyethylene Glycol P-isooctylphenyl, octoxynol-9(Triton X-100); And nonoxynol series, they are the polyoxyethylene nonyl phenylates with various number ethylene oxide units, as nonoxydol 9 and nonoxydol 10.The advantage of this class material is that it uses in the present invention and kills sperm cell characteristics in addition.The polyoxyethylene groups non-ionic surface active agent that another type is suitable for is a polyoxy ethanol, as the compound of commercially available commodity " Siponic " by name.But " non-ionic surface active agent " Dekker that the selection reference standard reference book W.J.Schick of other surfactant writes, New York, 1967.Most important selection criteria be on selected consumption can with skin and selected strong disinfectant can be miscible.
Other component in the present composition is a kind of non-toxicity time abnormal former water-soluble thickener and water, and its proportioning should be suitable for providing a kind of gel semi-solid products that is similar to the denseness of wiping hand missible oil that has.Many these class thickeners have commercially available, are generally used in the preparation industry of cosmetics and medicine.They are known to those skilled in the art.Various cellulose derivativess are suitable for this purposes, for example methylcellulose and various sodium carboxymethylcellulose, and as carbomer 910,934,934p, 940,941 and 1342; And carbopels 940,941 and 930(Goodyear provide).Preferably also can provide the to a certain degree compound of lubrication for final composition.Preferential especially is ultrasonic coupling agent, a kind of usually on diasonograph as the gel combination that contact with skin, this suitable 1-80%(weight that comprises), preferred 20-80%(weight), the composition of 30-40%(weight most preferably).Consumption can be selected according to desired denseness of final products and the concrete thickener of selecting (thickening power that some of them are stronger than having of other).
Various other components also can add in the composition of the present invention to improve proterties, make that people are glad to use.Thereby wherein can contain one or more softening agents such as glycerine, lanolin, aloe black false hellebore, paraffin oil, glycerine monoester, myrj compound, tween, DEG compound, with dodecyl sodium sulfate etc. or two or more mixture wherein, with the lubricity of improving composition and general oiliness.Can add various pastils and colouring agent if desired; The all necessary and skin-compatible of the combination of any use has the inertia to mobile component, nature, and its usage amount can not cause the instability of integral formulation emulsion denseness.
Can use the cosmetics of standard or medicine gel preparation steps and equipment to be prepared by prescription of the present invention.The adding of component, mixing temperature etc. are not had special key request, if can obtain a kind of uniformly, have an end-product of quite stable.
According to the concrete most preferably prescription of the present invention following formation (by weight) is arranged:
Water 53.74
Ultrasonic coupling agent (aquasonic gel) 42.50
Glycerine 2.27
Aloe black false hellebore oil 1.19
Triton X-100 0.10(octoxynol-9)
MQ2525-50% 0.05
Aromatic (Vanilla plant extracts) 0.15
The present invention is further described and illustrates in following concrete, non-limiting example.
Embodiment 1
According to the present invention, the emulsion formulations of a kind of semisolid, emulsion form thickness constitutes (percentage by weight) by following ingredients:
EDTA tetrasodium salt 0.05
octoxynol-9(TritonX-100) 0.02
BTC-2125 0.05
Glycerine 0.05
Methylcellulose (4000 cps) 1.0
Siponic c-20 5.0
Water 93.83
Preparation is at room temperature carried out, and said components is mixed in a container simply, tests its antiviral efficacy to human herpes 1 type and 2 type viruses then in vitro.
The bleb of Mi Nisi suddenly 1 type that obtains and the concrete clinical separation strain of 2 types virus are:
1 type separated strain 103,104,105,117.
2 type separated strains 109,106,142.
Viral suspension behind low-speed centrifugal, clarify and-70 ℃ frozen, its appeal is titrated and represent with TCID 50/0.1ml.
Virus with volume adds in the test formulations with the given concentration of result in the following form.Thereby emulsion is 10% adding virus back Cmax.
The mixed liquor that moves into virus was cultivated 10 minutes down at 22 ℃, soon with 10 times of dilutions of solvent of cooling off, use 4 solencyte cultures to determine residual infection power to every pipe dilution factor then, the result expresses with TCID 50/0.1ml, uses the solvent of no test formulations to organize in contrast.
After the cultivation, test formulations concentration is 10,5,2.5,1 in all test formulations/virus mixture, and 0.5,0.05% o'clock, test formulations residue virus activity was reduced to the level that can not detect.Solvent-laden control group activity is equivalent to 3.0 and 4.0log
10TCID 50/0.1ml.With concentration be 105,2.5,1,0.5, after the contact of 0.05% test formulations, the reduction amount of titration of virus surpasses 2log
10TCID
30
For confirming above-mentioned experiment, test formulations/viral mixture was cultivated 10 minutes down at 37 ℃, was obtained the result of same inactivation by two types of exanthema virus.
Embodiment 2-Study on Virulence
The identical component that emulsion is described by above-mentioned example 1 is prepared with same relative scale.
The arm of 10 mouse is shaved hair expose epidermis, and be coated with emulsion in the exposed region part of each mouse, and observed 48 hours, the result is as follows:
The result
Mouse number of applications virulence
1 1 -
2 1 -
3 1 -
4 1 -
5 1 -
6 4
*-
7 4 -
8 4 -
9 4 -
(connecting table)
10 4 -
There is sign in-indication no visible virulence in 48 hours.
* emulsion served as to amount at interval to be coated with 4 times with 4 hours.
Embodiment 3
In metamorphosis test and failure test, according to above-mentioned this effect detailed, that prepreerence emulsion formulations is tested its anti-viruses of human hepatitis B that gives.
Viruses of human hepatitis B (HBD) liquid forms (Gilbralter biology laboratory by 5.0% calf serum (40ml) and 760 μ l HBD mixed preparing, Inc, HBV storehouse 11GBL reference number 018-272A-153) 2ml emulsion formulations and 0.2ml HBV prescription liquid are injected in 25 * 150mm glass tube the violent vortex of mixture 1 minute.Add 18ml and contain the trypticase soya broth cessation reaction of 2% serum, fully vortex and put and use ice bath.The virus control group is added to the same manner preparation of 2.0ml phosphate buffered saline(PBS) (PBS) by absorption 0.2ml HBV.Reactant mixture concentrates after with suitable sucrose gradient ultracentrifugation, and supernatant discards gently, and the precipitation agglomerate suspends again with 0.5ml PBS, and similar agglomerate is merged.The HBV particle is 60~65%.(sucrose) is with (late-zonal) ultracentrifugation purifying and fractionated under the linear gradient through late.The Dane particle fragment of refractive index between 1.396 and 1.404 is saved and concentrates standby.
Positive staining is used for the virion number that quantitatively destroyed by test formulations, and operating procedure is to add 2% potassium permanganate and inhale and go, and adds deionized water and inhales and go, and adds 1.5% uranium acetate, and inhales and go., count under 50,000 multiplication factors from 20 foursquare 10 visuals field of selecting at random with the Karen Phillips transmission electron microscope observing.Do not detect virion.Relatively control group confirms destroyed in 1 minute above 40,000 virion.
Negative staining is used for detecting the virion that changes on the form.The method in this step is to use the 5% uranium acetate aqueous solution of pH3.5, and suction is gone.In 30 or the more visual field of Karen Phillips transmission electron microscope from 6 squares of selecting at random, observe and thoroughly count four covert APO, APO
1, APO
2And AP
3In each is covert.At AP
2And AP
3Go up mutually, the virion that is observed is all impaired on form, and is the height metamorphosis, and these viruses have not had appeal.On the contrary, contrast is marked on AP
0Or AP
1Can be observed obvious int virion on form in a large number mutually, and have contagiosity.
The mechanism of action of the present composition may be breaking of virosomal membrane.
Embodiment 4
Concrete according to the present invention, most preferred prescription carries out the inactivation of the MIV in vitro test of emulsion.
People T-chronic myeloid leukemia 1 type virus permanent cell line (MT-2) is stored in (Dulbecco's improvement Eagle's medium on the growth medium, contain 15% heat inactivation hyclone, the 2mm glutamine, the streptomycin of the penicillin of every ml 100iu and every ml 100 μ g).
HIV-1(III B) the prototype experiment strain is to obtain from H9 infection cell culture supernatant, is concentrated to 1000 times by tape transport in sucrose.The Strain that filters is by whole branch and be stored in-85 ℃ until application.Strain is determined with a kind of end last titration of MT-2 cell on one 96 hole microtitre slab construction eventually.Strain contains TCID 50 virus titers of 5.50log10 TCID 50/ml, adopts the Reed-Muench method to calculate.
For carrying out Study of cytotoxicity, the MT-2 cell just is exposed to various dilution compounds in the initial growth phase, and after 4 days, cell survival rate is estimated by the Tryptan-Glu exclusive method, and compared with no medicine.
Strain is melted the back and is diluted to obtain the necessary required virus quantity of inactivation method test with phosphate buffered saline(PBS).Untreated virus is as the TCID of this test
50Contrast was exposed to HIV-this compound after 1 minute, handled and untreated virus, and contrast is with the continuous 10 times of dilutions of PBS liquid, and every part of dilution is used to infect the MT-2 cell with the method for past description.Expressing viral is monitored by the existence of plasomidum structure.The plasomidum that HIV induces is formed on to cultivate and uses a kind of plasomidum formation detection method to assess after 6 days.
When be exposed to (23-27 ℃) under room temperature untreated control group after 1 minute relatively the time, make the HIV appeal reduce by The compounds of this invention greater than 2.5log10TCID 50/ml.
Embodiment 5
By compare the most preferably emulsion effect of prescription that assessment the present invention is concrete with commercially available surgery emgloves.
By above-mentioned prescription, patient's both hands are coated with double emulsion, and every hand consumption approximately is 2 1/2 CC'S, and both hands are put on surgical glove more then.Under a kind of situation, the emulsion gloves are containing residual starch based powdered lubricant under the form usually.Another situation, gloves do not contain crocus.Gloves were stayed the user 16 hours on hand.
Remove gloves, centrifugal, the liquid/semi-solid content (remaining emulsion, user's sweat, crocus precipitation etc.) in the gloves is got rid of in the fingerstall.Extract these liquid residue after the merging, by the serial dilution technology of anti-HIV prototype experiment strain, carry out external HIV inactivation experiment, the virus titer of this anti-HIV prototype experiment strain uses MT-2 cell and 10 times of serial dilutions as described in the example 4.
The emgloves residue and the emgloves residue that contains crocus that do not contain crocus all show to make the log virus titer reduce greater than 3.0.As the emulsion effect of carrying out the emgloves test.And then proof is still kept it under at least 16 hours the situation and is made the virally inactivated characteristic of HIV mixing with emgloves by composition of the present invention.
Claims (14)
1, is applicable to and is placed on a health part to suppress the latex barrier item of virus to the propagation of this place, above-mentioned latex barrier item have an outer surface and with the inner surface of Body contact, should one deck semisolid be arranged interior table surface, antivirus gel or missible oil wherein contain the alkylaryl quaternary ammonium halide disinfectant of the 0.005-0.1% that has an appointment (weight);
A kind of nonionic or cationic surfactant, content are 0.01-0.1% (weight);
A kind of nonionic time abnormal former and mixable thickener of water, its content is 1-80% (weight).
2,, mean a kind of latex surgical glove or a kind of latex prophylactic according to the latex barrier item of claim 1.
3, according to the latex barrier item of claim 2, wherein exist the disinfectant that accounts for the about 0.005-0.05% of weight.
4,, wherein exist the disinfectant of 0.005-0.01% amount by weight percentage according to the latex barrier item of claim 3.
5, according to the latex barrier item in the claim 3, wherein used disinfectant is selected from zephiran, and wherein alkyl is C
12-C
18Alkyl; And the alkyl dimethyl ethylbenzylammonium chloride, wherein alkyl is C
12-C
18Alkyl; And their mixture.
6, according to the latex protective device of claim 4, wherein the content of surfactant is 0.01-0.05%(weight).
7, according to the latex barrier item of claim 6, wherein surfactant is a kind of non-ionic surface active agent of polyethylene glycol oxide fundamental mode.
8, according to the latex barrier item of claim 7, wherein surfactant is oxtorynol-9.
9, according to the latex barrier item of claim 3, wherein thickener is a ultrasonic coupling agent.
10, according to the latex barrier item of claim 9, wherein the content of ultrasonic coupling agent is 30-40%(weight).
11, according to the latex barrier item of claim 3, wherein antivirus gel or emulsion contain softening agent.
12, according to the latex barrier item of claim 11, wherein softening agent is a glycerine.
13, a kind of semi-solid antivirus gel or emulsion compositions that is applied to mammiferous local skin under the viral barrier item, said composition contains a kind of alkyl benzyl quaternary ammonium halide disinfectant, and application quantity is the 0.005-0.1% percentage by weight;
A kind of nonionic or cationic surfactant, content are with restatement 0.01-0.1%;
A kind of nonionic time abnormal former and mixable thickener of water, accounting for weight is 1-80%;
And water.
14, composition according to claim 13, wherein disinfectant is selected from zephiran, and wherein alkyl is C
12-C
18Alkyl;
Alkyl dimethyl Ethylbenzyl chlorination thing, wherein alkyl is C
12-C
18Alkyl;
With and composition thereof.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN93103567A CN1092937A (en) | 1993-04-02 | 1993-04-02 | A kind of antiviral coating that can be used for the latex viral barrier items such barrier item |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN93103567A CN1092937A (en) | 1993-04-02 | 1993-04-02 | A kind of antiviral coating that can be used for the latex viral barrier items such barrier item |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1092937A true CN1092937A (en) | 1994-10-05 |
Family
ID=4984687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN93103567A Pending CN1092937A (en) | 1993-04-02 | 1993-04-02 | A kind of antiviral coating that can be used for the latex viral barrier items such barrier item |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1092937A (en) |
-
1993
- 1993-04-02 CN CN93103567A patent/CN1092937A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0439513B1 (en) | Composition for inhibiting transmission of aids | |
| US5370876A (en) | Antimicrobial protective skin composition and method for protecting skin from body fluids | |
| AU2004273779B2 (en) | Compositions for inactivating pathogenic microorganisms, methods of making the compositions, and methods of use thereof | |
| KR100356882B1 (en) | Zinc Gluconate Gel Composition | |
| JP2005514325A (en) | Compositions and methods of antimicrobial nanoemulsions | |
| Weber et al. | Chemical condoms’ for the prevention of HIV infection: evaluation of novel agents against SHIV89. 6PDin vitro and in vivo | |
| US20050232895A1 (en) | Anti-viral pharmaceutical compositions | |
| Briz et al. | Development of water-soluble polyanionic carbosilane dendrimers as novel and highly potent topical anti-HIV-2 microbicides | |
| JP2003519184A (en) | Antimicrobial compositions and methods of use | |
| US5387611A (en) | Use of butylurea, nonoxynol-9 and benzalkonium chloride as anti-bacterial, anti-viral contraceptive agents | |
| WO1993018745A1 (en) | Use of antiviral coating for latex items such as condoms | |
| Sepúlveda-Crespo et al. | Sulfonate-ended carbosilane dendrimers with a flexible scaffold cause inactivation of HIV-1 virions and gp120 shedding | |
| JP2002515410A (en) | Broad spectrum disinfecting and spermicidal compositions, devices and methods | |
| Roy et al. | Thermoreversible gel formulations containing sodium lauryl sulfate or n-lauroylsarcosine as potential topical microbicides against sexually transmitted diseases | |
| CN88101699A (en) | The method that suppresses cransmission of AIDS virus | |
| CN1092937A (en) | A kind of antiviral coating that can be used for the latex viral barrier items such barrier item | |
| EP2257263A1 (en) | Topical formulations for the prevention of sexually transmitted disease and methods of producing the same | |
| RU2175247C1 (en) | Antiseptic composition and method of its preparing | |
| US20080081797A1 (en) | Topical formulations for the prevention of sexually transmitted disease and methods of producing the same | |
| Arotiba et al. | Human immuno-deficiency virus (HIV) infection among oral surgery patients at the University College Hospital, Ibadan, Nigeria | |
| FI128711B (en) | Treatment of herpes simplex symptoms on skin and mucous membrane of mammals | |
| JP2010209109A (en) | Composition and method for anti-microbial nanoemulsion | |
| CA2781379C (en) | Topical formulations for the prevention of sexually transmitted disease and methods of producing the same | |
| US20210330698A1 (en) | Methods and compositions for inhibiting enveloped viruses using low molecular weight hydrophobically modified polymers | |
| US8409557B2 (en) | Topical formulations for the prevention of sexually transmitted disease and methods of producing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C01 | Deemed withdrawal of patent application (patent law 1993) | ||
| WD01 | Invention patent application deemed withdrawn after publication |